Equity Overview
Price & Market Data
Price: $33.22
Daily Change: -$0.415 / 1.25%
Daily Range: $33.00 - $33.87
Market Cap: $2,552,159,488
Daily Volume: 132,048
Performance Metrics
1 Week: 8.49%
1 Month: 0.33%
3 Months: -6.89%
6 Months: -16.44%
1 Year: -21.21%
YTD: -15.59%
Company Details
Employees: 327
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.